James D Mellor

Medicine · Health Sciences

10h-index697citations22works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(6), Colorectal Cancer Treatments and Studies(6), Pharmaceutical studies and practices(4), Glycosylation and Glycoproteins Research(3), Genetic factors in colorectal cancer(3)

Publications22 total

Primer Sequences from Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
2023Open Access
Data from Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
2023Open Access
Primer Sequences from Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
2023Open Access
Data from Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
2023Open Access
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
Clinical Cancer Research·2016· 37 cited
<scp>A</scp>ustralian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel
Internal Medicine Journal·2014· 32 citedOpen Access
Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic
Asia-Pacific Journal of Clinical Oncology·2014· 34 cited
Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma
The Medical Journal of Australia·2014· 62 cited
A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll
Journal of Oncology Pharmacy Practice·2013· 4 cited
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
Journal of Hematology & Oncology·2013· 416 citedOpen Access
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital
Asia-Pacific Journal of Clinical Oncology·2012· 9 cited
Complementary and Alternative Medicines Use by Cancer Patients and the Role of the Drug Information Pharmacist
Journal of Pharmacy Practice and Research·2012
Thalidomide thromboprophylaxis in multiple myeloma: A review of current evidence
Asia-Pacific Journal of Clinical Oncology·2012· 5 citedOpen Access
Access to anticancer drugs: many evidence‐based treatments are off‐label and unfunded by the Pharmaceutical Benefits Scheme
Internal Medicine Journal·2012· 25 cited
Carmustine infusion reactions are more common with rapid administration
Supportive Care in Cancer·2012· 2 cited
An Unusual Case of Serotonin Syndrome with Oxycodone and Citalopram
Case Reports in Oncological Medicine·2012· 24 citedOpen Access
A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008
Australian Health Review·2011· 1 citedOpen Access
Clinical guidance on the perioperative use of targeted agents in solid tumor oncology
Asia-Pacific Journal of Clinical Oncology·2011· 18 cited
Drug Interactions Between Anti‐Epileptics and Chemotherapeutic Drugs: Value of a Pre‐Treatment Pharmaceutical Review
Journal of Pharmacy Practice and Research·2011· 1 citedOpen Access
Off label and unlicensed prescribing in a specialist oncology center in Australia
Asia-Pacific Journal of Clinical Oncology·2009· 10 cited
page 1 of 2Next →

Frequent Co-authors

Alexander Dobrovic(6), Sue Kirsa(6), Geoffrey Liu(5), Dongsheng Tu(5), Marcia Lewis(5), Dangxiao Cheng(5), Leslie A. Sullivan(5), Zhuo Chen(5), Eric Morgen(5), John Simes(5), Timothy Price(5), Niall C. Tebbutt(5), Jeremy Shapiro(5), G. Mark Jeffery(5), Thomas Mikeska(5), Shakeel Virk(5), Lois E. Shepherd(5), Derek J. Jonker(5), Christopher J. O’Callaghan(5), Christos S. Karapetis(5)